Structure‐Based Bioisosterism Design, Synthesis, Antitumor and Toxicity Assessment of Novel Aplysinopsin Analogs
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Bárbara Gonçalves Rivello und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Medicinal Pharmaceutical Chemistry (LQFM), School of Pharmacy, Federal University of Goiás, Goiânia, Brazil. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Design. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Eight new LQFM's Aplysinopsin analogs ( 12a‐h ) were synthesized and were evaluated for their anticancer profile on MCF‐7 (breast cancer), SiHA and HeLa (cervical cancer). The compounds were obtained through the rational drug design strategy, bioisosterism, by changing the indole scaffold of Aplysinopsin by phenylpyrazole, a subunit extensively explored for designing potent and selective anticancer agents. The synthesis was performed in three simple steps, followed by structural elucidation through nuclear magnetic resonance, infrared spectroscopy, and mass spectrometry, and global yield ranged from 10% to 93%. Regarding the biological assay, the best result was achieved with 12g , which showed antiproliferative activity against all cell lines evaluated, with IC 50 59.22, 58.33, and 55.32 μM for MCF‐7, SiHA and HeLa, respectively. The safety profile, in the Zebrafish‐based model, showed the mortality rate for 12g in concentration‐time‐dependent, from 87 μM, over 120 h. All Aplysinopsin analogs demonstrated drug‐likeness in agreement to Lipinski and Veber rules. Although the moderate antiproliferative activity displayed by 12g , our results include new Aplysinopsin analogs that may be promising lead compounds for further studies, since chemical structures related to this marine compound have provided satisfactory results as anticancer agents against a variety of human tumor cell lines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Medicinal Pharmaceutical Chemistry (LQFM), School of Pharmacy, Federal University of Goiás, Goiânia, Brazil.
- Laboratory of Biochemical and Cytological Analysis, Postgraduate Program in Pharmaceutical Sciences, School of Pharmacy, Federal University of Rio Grande Do Sul, Porto Alegre, Brazil.
- Environmental Toxicology Research Laboratory (EnvTox), School of Pharmacy, Federal University of Goiás, Goiânia, Brazil.
- School of Pharmacy, Federal University of Bahia, Salvador, Brazil.
- Nuclear Magnetic Resonance Laboratory (LabRMN), Institute of Chemistry, Federal University of Goiás, Goiânia, Brazil.
ORCID-Profile: Jéssica Gotardi, Michele Resende Machado, Gloria Narjara Santos da Silva, Luciano Morais Lião
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Rivello, B. G., Willig, J. B., Gotardi, J., Machado, M. R., da Silva, G. N. S., Gomides, C. D., de Oliveira, G. A. R., Lião, L. M., Pilger, D. A., & Menegatti, R. (2025). Structure‐Based Bioisosterism Design, Synthesis, Antitumor and Toxicity Assessment of Novel Aplysinopsin Analogs. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70151
Vancouver
Rivello BG, Willig JB, Gotardi J, Machado MR, da Silva GNS, Gomides CD, et al. Structure‐Based Bioisosterism Design, Synthesis, Antitumor and Toxicity Assessment of Novel Aplysinopsin Analogs. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70151
BibTeX
@article{Rivello2025,
author = {Rivello, Bárbara Gonçalves and Willig, Julia Biz and Gotardi, Jéssica and Machado, Michele Resende and da Silva, Gloria Narjara Santos and Gomides, Christian Dias and de Oliveira, Gisele Augusto Rodrigues and Lião, Luciano Morais and Pilger, Diogo André and Menegatti, Ricardo},
title = {Structure‐Based Bioisosterism Design, Synthesis, Antitumor and Toxicity Assessment of Novel Aplysinopsin Analogs},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70151}
}
EUVIMED